SCHEMBL6404374

SCHEMBL6404374

O=C(Cc1cccc(O)c1)c1c(O)cccc1SP(=O)(O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
CTBP2 P56545 1/20 0.40
IDO1 P14902 1/20 0.37
ALOX5 P09917 1/20 0.36
HIF1A Q16665 1/20 0.36
ACHE P22303 1/20 0.36
SGMS1 Q86VZ5 1/20 0.36
SGMS2 Q8NHU3 1/20 0.36
PPIA P62937 1/20 0.35
ANPEP P15144 1/20 0.35
ERAP2 Q6P179 1/20 0.35
ERAP1 Q9NZ08 1/20 0.35
ENPP2 Q13822 1/20 0.35
MAPT P10636 2/20 0.35
PIK3CA P42336 2/20 0.35
MEN1 O00255 1/20 0.35
CYP3A4 P08684 1/20 0.35
HPGD P15428 1/20 0.35
MAPK1 P28482 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6396393 0.88 LMNA (0.46) LMNACTBP2ALOX5HIF1AMAPT
SCHEMBL6399712 0.87 SLC5A1 (0.48) LMNAIDO1ACHESGMS1SGMS2
SCHEMBL6396177 0.86 ACHE (0.43) LMNAALOX5ACHESGMS1SGMS2
SCHEMBL6403057 0.85 ACHE (0.50) IDO1ACHESGMS1SGMS2ANPEP
SCHEMBL6396964 0.80 HIF1A (0.44) LMNACTBP2IDO1ALOX5HIF1A
SCHEMBL6396066 0.80 HIF1A (0.42) LMNACTBP2IDO1ALOX5HIF1A
SCHEMBL6404380 0.80 CTBP2 (0.42) LMNACTBP2ALOX5HIF1AACHE
SCHEMBL6401991 0.77 HDAC4 (0.36) LMNAHIF1AMAPTCYP3A4HPGD
SCHEMBL6403464 0.76 INPPL1 (0.41) LMNACTBP2HIF1APPIAMAPT
SCHEMBL6397017 0.76 CYP19A1 (0.54) LMNAACHESGMS1SGMS2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 LMNA 4647/4885CTBP2 1783/4885IDO1 3238/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 LMNA 4664/4885CTBP2 1802/4885IDO1 2855/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 LMNA 4647/4885CTBP2 1783/4885IDO1 3238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.